Stay updated on LAG-3 in GBM: Alone & with Nivolumab Clinical Trial
Sign up to get notified when there's something new on the LAG-3 in GBM: Alone & with Nivolumab Clinical Trial page.

Latest updates to the LAG-3 in GBM: Alone & with Nivolumab Clinical Trial page
- Check6 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check14 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.9%
- Check21 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check28 days agoNo Change Detected
- Check43 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check57 days agoChange DetectedThe webpage has undergone significant updates, including the removal of detailed information about a Phase I trial involving anti-LAG-3 and anti-CD137 treatments for recurrent glioblastoma, while adding new identifiers and collaborators related to the study.SummaryDifference42%
- Check64 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
Stay in the know with updates to LAG-3 in GBM: Alone & with Nivolumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LAG-3 in GBM: Alone & with Nivolumab Clinical Trial page.